Experimental autoimmune encephalomyelitis in NF-κB-deficient mice: Roles of NF-κB in the activation and differentiation of autoreactive T cells

Journal of Immunology

Volumn 163, Issue 5, 1999, Pages 2937-2943

  Hilliard, Brendan ^a   Samoilova, Elena B ^a   Liu, Tzu Shang T ^a   Rostami, Abdolmohamad ^a   Chen, Youhai ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FLOW CYTOMETRY; HELPER CELL; HISTOPATHOLOGY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD45; ANTIGENS, CD80; CELL DIFFERENTIATION; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNITY, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; NF-KAPPA B; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 0033198141     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Beg, A. A., and D. Baltimore. 1996. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274:782.
2. Beg, A. A., W. C. Sha, R. T. Bronson, S. Ghosh, and D. Baltimore. 1995. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 376:167.
3. Sha, W. C., H. C. Liou, E. I. Tuomanen, and D. Baltimore. 1995. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 80:321.
4. Barnes, P. J., and M. Karin. 1997. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1066.
5. Kaltschmidt, B., M. Uherek, B. Volk, P. A. Baeuerle, and C. Kaltschmidt. 1997. Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA 94:2642.
6. Kaltschmidt, C., B. Kaltschmidt, J. Lannes-Vieira, G. W. Kreutzberg, H. Wekerle, P. A. Baeuerle, and J. Gehrmann. 1994. Transcription factor NF-κB is activated in microglia during experimental autoimmune encephalomyelitis. J. Neuroimmunol. 55:99.
7. Kaltschmidt, C., B. Kaltschmidt, H. Neumann, H. Wekerle, and P. A. Baeuerle. 1994. Constitutive NF-κB activity in neurons. Mol. Cell. Biol. 14:3981.
8. Thomas, L. H., J. S. Friedland, M. Sharland, and S. Becker. 1998. Respiratory syncytial virus-induced RANTES production from human bronchial epithelial cells is dependent on nuclear factor-κB nuclear binding and is inhibited by adenovirus-mediated expression of inhibitor of κB α. J. Immunol. 161:1007.
9. Ting, A. T., F. X. Pimentel-Muinos, and B. Seed. 1996. RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J. 15:6189.
10. Ishikawa, H., E. Claudio, D. Dambach, C. Raventos-Suarez, C. Ryan, and R. Bravo. 1998. Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-κB1) but expressing p50. J. Exp. Med. 187:985.
11. Liu, S. F., X. Ye, and A. B. Malik. 1997. In vivo inhibition of nuclear factor-KB activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J. Immunol. 159:3976.
12. Wingren, A. G., E. Parra, M. Varga, T. Kalland, H. O. Sjogren, G. Hedlund, and M. Dohlsten. 1995. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit. Rev. Immunol. 15:235.
13. Caamano, J. H., C. A. Rizzo, S. K. Durham, D. S. Barton, C. Raventos-Suarez, C. M. Snapper, and R. Bravo. 1998. Nuclear factor (NF)-κB2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J. Exp. Med. 187:185.
14. Franzoso, G., L. Carlson, L. Poljak, E. W. Shores, S. Epstein, A. Leonardi, A. Grinberg, T. Tran, T. Scharton-Kersten, M. Anver, et al. 1998. Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J. Exp. Med. 187:147.
15. Doi, T. S., T. Takahashi, O. Taguchi, T. Azuma, and Y. Obata. 1997. NF-κB RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J. Exp. Med. 185:953.
16. Weih, F., D. Carrasco, S. K. Durham, D. S. Barton, C. A. Rizzo, R. P. Ryseck, S. A. Lira, and R. Bravo. 1995. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 80:331.
17. Gerondakis, S., A. Strasser, D. Metcalf, G. Grigoriadis, J. Y. Scheerlinck, and R. J. Grumont. 1996. Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor. Proc. Natl. Acad. Sci. USA 93:3405.
18. Samoilova, E. B., J. L. Horton, B. Hilliard, T. S. Liu, and Y. Chen. 1998. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161:6480.
19. Chen, Y., V. K. Kuchroo, J.-I. Inobe, D. A. Hafler, and H. L. Weiner. 1994.Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265:1237.
20. Chen, Y., J. Inobe, R. Marks, P. Gonnella, V. K. Kuchroo, and H. L. Weiner. 1995. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376:177.
21. Moore, G. R., U. Traugott, M. Farooq, W. T. Norton, and C. S. Raine. 1984. Experimental autoimmune encephalomyelitis: augmentation of demyelination by different myelin lipids. Lab. Invest. 51:416.
22. Baldwin, A. S., Jr. 1996. The NF-κB and IκB proteins: new discoveries and insights. Anna. Rev. Immunol. 14:649.
23. Zhao, J., G. J. Freeman, G. S. Gray, L. M. Nadler, and L. H. Glimcher. 1996. A cell type-specific enhancer in the human B7.1 gene regulated by NF-κB. J. Exp. Med. 183:777.
24. Pimentel-Muinos, F. X., J. Mazana, and M. Fresno. 1995. Biphasic control of nuclear factor-κB activation by the T cell receptor complex: role of tumor necrosis factor α. Eur. J. Immunol. 25:179.
25. Rensing-Ehl, A., S. Hess, H. W. Ziegler-Heitbrock, G. Riethmuller, and H. Engelmann. 1995. Fas/Apo-1 activates nuclear factor κB and induces interleukin-6 production. J. Inflamm. 45:161.
26. Los, M., H. Schenk, K. Hexel, P. A. Baeuerle, W. Droge, and K. Schulze-Osthoff. 1995. IL-2 gene expression and NF-κB activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J. 14:3731.
27. Munoz, C., D. Pascual-Salcedo, M. C. Castellanos, A. Alfranca, J. Aragones, A, Vara, M. J. Redondo, and M. O. de Landazuri. 1996. Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-κB and AP-1 transcription factors activity. Blood 88:3482.
28. O'Neill, L. A., and C. Kaltschmidt. 1997. NF-κB: a crucial transcription factor for glial and neuronal cell function. Trends Neurcsci. 20:252.
29. Stricker, K., E. Serfling, P. H. Krammer, and W. Falk. 1993. An NF-κB-like element plays an essential role in interleukin-1-mediated costimulation of the mouse interleukin-2 promoter. Ear. J. Immunol. 23:1475.
30. Van Antwerp, D. J., S. J. Martin, T. Kafri, D. R. Green, and I. M. Verma. 1996. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274:787.
31. Wang, C. Y., M. W. Mayo, R. G. Korneluk, D. V. Goeddel, and A. S. Baldwin, Jr. 1998. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-1AP2 to suppress caspase-8 activation Science 281:1680.
32. Mayo, M. W., C. Y. Wang, P. C. Cogswell, K. S. Rogers-Graham, S. W. Lowe, C. J. Der, and A. S. Baldwin, Jr. 1997. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278: 1812.
33. Wang, C. Y., M. W. Mayo, and A. S. Baldwin, Jr. 1996. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274:784.
34. Wu, M., H. Lee, R. E. Bellas, S. L. Schauer, M. Arsura, D. Katz, M. J. FitzGerald, T. L. Rothstein, D. H. Sherr, and G. E. Sonenshein. 1996. Inhibition of NF-κB/ Rel induces apoptosis of murine B cells. EMBO J. 15:4682.
35. Liu, Z. G., H. Hsu, D. V. Goeddel, and M. Karin. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87:565.
36. Wu, M. X., Z. Ao, K. V. Prasad, R. Wu, and S. F. Schlossman. 1998. IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science 281: 998.
37. Lai, J. H., G. Horvath, J. Subleski, J. Bruder, P. Ghosh, and T. H. Tan. 1995. RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol. Cell. Biol.. 15:4260.
38. Vanderlugt, C. L., S. M. Rahbe, P. J. Elliott, M. C. Dal Canto, and S. D. Miller. 1999. Chronic treatment of SJL mice with the proteasome inhibitor PS-519 inhibits the progression of relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. In press.